FDA Determines Regulatory Review Period for VABYSMO Patent Extension

Summary

The Food and Drug Administration (FDA) has published a notice determining the regulatory review period for VABYSMO, a human biological product, following submissions to the US Patent and Trademark Office (USPTO) for patent extension.